| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 23 | 2024 | 315 | 5.020 |
Why?
|
| Kidney | 46 | 2024 | 1110 | 4.820 |
Why?
|
| Lupus Nephritis | 13 | 2023 | 78 | 2.970 |
Why?
|
| Thrombotic Microangiopathies | 6 | 2024 | 20 | 2.450 |
Why?
|
| Kidney Neoplasms | 11 | 2025 | 546 | 2.370 |
Why?
|
| Glomerulonephritis | 17 | 2022 | 80 | 2.120 |
Why?
|
| Kidney Glomerulus | 20 | 2023 | 121 | 2.110 |
Why?
|
| Kidney Transplantation | 23 | 2023 | 870 | 2.070 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2025 | 361 | 1.930 |
Why?
|
| Nephrectomy | 13 | 2025 | 293 | 1.870 |
Why?
|
| Pediatrics | 4 | 2025 | 386 | 1.830 |
Why?
|
| Kidney Failure, Chronic | 9 | 2024 | 429 | 1.790 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2024 | 234 | 1.780 |
Why?
|
| Biopsy | 21 | 2021 | 1177 | 1.620 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 10 | 2023 | 36 | 1.520 |
Why?
|
| Cardiology | 2 | 2025 | 120 | 1.410 |
Why?
|
| Heart Defects, Congenital | 5 | 2025 | 367 | 1.220 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 395 | 1.210 |
Why?
|
| Nephritis, Interstitial | 8 | 2016 | 44 | 1.200 |
Why?
|
| Diabetic Nephropathies | 7 | 2020 | 89 | 1.150 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2025 | 256 | 1.110 |
Why?
|
| Podocytes | 11 | 2023 | 34 | 1.100 |
Why?
|
| Hospitals, Pediatric | 4 | 2024 | 128 | 1.080 |
Why?
|
| Humans | 125 | 2025 | 93615 | 1.050 |
Why?
|
| Global Health | 3 | 2025 | 208 | 1.000 |
Why?
|
| Autoimmunity | 5 | 2024 | 189 | 0.970 |
Why?
|
| Graft Rejection | 11 | 2023 | 1122 | 0.970 |
Why?
|
| Complement Activation | 6 | 2024 | 84 | 0.940 |
Why?
|
| Kidney Medulla | 2 | 2015 | 77 | 0.870 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2024 | 2 | 0.860 |
Why?
|
| Organizational Innovation | 1 | 2024 | 40 | 0.850 |
Why?
|
| Allografts | 3 | 2021 | 205 | 0.850 |
Why?
|
| Incidental Findings | 2 | 2019 | 97 | 0.830 |
Why?
|
| Hepatorenal Syndrome | 2 | 2014 | 9 | 0.800 |
Why?
|
| Lysosomes | 1 | 2024 | 123 | 0.800 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2014 | 23 | 0.790 |
Why?
|
| Bile | 2 | 2014 | 60 | 0.790 |
Why?
|
| Bilirubin | 2 | 2014 | 133 | 0.780 |
Why?
|
| Glomerulonephritis, Membranous | 6 | 2020 | 23 | 0.780 |
Why?
|
| Thrombosis | 3 | 2015 | 309 | 0.780 |
Why?
|
| Cause of Death | 2 | 2024 | 273 | 0.770 |
Why?
|
| Anemia, Sickle Cell | 2 | 2015 | 146 | 0.750 |
Why?
|
| Health Equity | 1 | 2025 | 102 | 0.750 |
Why?
|
| Kidney Tubules | 4 | 2014 | 91 | 0.730 |
Why?
|
| Inflammation | 11 | 2022 | 1049 | 0.730 |
Why?
|
| Nephrosclerosis | 2 | 2020 | 5 | 0.730 |
Why?
|
| Medical Records | 3 | 2012 | 122 | 0.720 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2022 | 506 | 0.710 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 4 | 2015 | 23 | 0.710 |
Why?
|
| Female | 67 | 2024 | 48779 | 0.680 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 453 | 0.680 |
Why?
|
| Pathology | 2 | 2012 | 36 | 0.670 |
Why?
|
| Nephritis | 2 | 2018 | 17 | 0.660 |
Why?
|
| Male | 65 | 2024 | 44578 | 0.660 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 17 | 0.630 |
Why?
|
| T-Lymphocytes | 5 | 2024 | 1275 | 0.630 |
Why?
|
| Child | 18 | 2025 | 7359 | 0.620 |
Why?
|
| Bowman Capsule | 2 | 2018 | 6 | 0.610 |
Why?
|
| Neurofibromatosis 2 | 1 | 2019 | 13 | 0.610 |
Why?
|
| Arteriosclerosis | 1 | 2020 | 106 | 0.610 |
Why?
|
| Acute Kidney Injury | 6 | 2019 | 339 | 0.600 |
Why?
|
| Complement Factor H | 9 | 2022 | 34 | 0.600 |
Why?
|
| Nephrotic Syndrome | 4 | 2021 | 33 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 496 | 0.600 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 189 | 0.570 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2014 | 160 | 0.550 |
Why?
|
| Intraoperative Complications | 2 | 2017 | 195 | 0.530 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 183 | 0.530 |
Why?
|
| Adrenalectomy | 1 | 2017 | 41 | 0.530 |
Why?
|
| Capillaries | 3 | 2014 | 83 | 0.530 |
Why?
|
| Autopsy | 5 | 2024 | 126 | 0.520 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 53 | 0.520 |
Why?
|
| Immune Complex Diseases | 5 | 2022 | 19 | 0.510 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 83 | 0.510 |
Why?
|
| Adult | 36 | 2021 | 27955 | 0.500 |
Why?
|
| Medical Tourism | 1 | 2016 | 6 | 0.490 |
Why?
|
| Renal Dialysis | 5 | 2024 | 350 | 0.490 |
Why?
|
| Intensive Care, Neonatal | 1 | 2016 | 14 | 0.480 |
Why?
|
| Erythrocytes | 2 | 2014 | 239 | 0.480 |
Why?
|
| Hemodynamics | 2 | 2017 | 714 | 0.480 |
Why?
|
| Precision Medicine | 1 | 2020 | 456 | 0.470 |
Why?
|
| Hemoglobin C Disease | 1 | 2015 | 5 | 0.470 |
Why?
|
| Inflammasomes | 2 | 2023 | 31 | 0.460 |
Why?
|
| Glomerular Filtration Rate | 5 | 2017 | 281 | 0.460 |
Why?
|
| Middle Aged | 36 | 2023 | 27621 | 0.460 |
Why?
|
| Severity of Illness Index | 7 | 2024 | 1918 | 0.450 |
Why?
|
| Antigen-Antibody Complex | 8 | 2021 | 88 | 0.450 |
Why?
|
| Cesarean Section | 1 | 2016 | 158 | 0.430 |
Why?
|
| Plasma Cells | 2 | 2012 | 84 | 0.430 |
Why?
|
| Mice | 36 | 2024 | 12233 | 0.430 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 98 | 0.420 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 67 | 0.410 |
Why?
|
| Algorithms | 3 | 2024 | 1954 | 0.410 |
Why?
|
| Aged | 26 | 2023 | 20469 | 0.400 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 88 | 0.400 |
Why?
|
| Autoantibodies | 5 | 2021 | 277 | 0.400 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 2491 | 0.400 |
Why?
|
| Immunohistochemistry | 14 | 2021 | 1790 | 0.390 |
Why?
|
| Cysts | 1 | 2014 | 99 | 0.390 |
Why?
|
| Research Report | 2 | 2015 | 43 | 0.390 |
Why?
|
| Postoperative Care | 1 | 2014 | 235 | 0.380 |
Why?
|
| Referral and Consultation | 1 | 2016 | 376 | 0.380 |
Why?
|
| Polyomavirus | 2 | 2017 | 16 | 0.380 |
Why?
|
| Animals | 43 | 2024 | 28041 | 0.380 |
Why?
|
| Disease Progression | 11 | 2022 | 1531 | 0.380 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 159 | 0.370 |
Why?
|
| Length of Stay | 1 | 2016 | 828 | 0.370 |
Why?
|
| Retrospective Studies | 17 | 2024 | 10186 | 0.360 |
Why?
|
| Laparoscopy | 4 | 2011 | 782 | 0.350 |
Why?
|
| Amyloidosis | 3 | 2020 | 132 | 0.350 |
Why?
|
| Macrophages | 5 | 2022 | 610 | 0.350 |
Why?
|
| Young Adult | 14 | 2021 | 6938 | 0.340 |
Why?
|
| Complement C4b | 3 | 2021 | 33 | 0.340 |
Why?
|
| Adaptive Immunity | 4 | 2019 | 179 | 0.340 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 63 | 0.340 |
Why?
|
| Carrier Proteins | 1 | 2014 | 660 | 0.330 |
Why?
|
| Signal Transduction | 7 | 2024 | 3498 | 0.330 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2010 | 36 | 0.330 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 3 | 2021 | 16 | 0.330 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 140 | 0.330 |
Why?
|
| Diffusion of Innovation | 2 | 2024 | 77 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 20 | 2024 | 3430 | 0.310 |
Why?
|
| Transplantation, Homologous | 7 | 2021 | 1014 | 0.310 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 147 | 0.300 |
Why?
|
| Cytokines | 2 | 2021 | 863 | 0.300 |
Why?
|
| Glomerular Basement Membrane | 3 | 2015 | 5 | 0.300 |
Why?
|
| Stem Cells | 1 | 2012 | 386 | 0.290 |
Why?
|
| Congresses as Topic | 1 | 2010 | 124 | 0.290 |
Why?
|
| Microscopy, Fluorescence | 7 | 2016 | 435 | 0.290 |
Why?
|
| Cell Lineage | 2 | 2017 | 320 | 0.290 |
Why?
|
| Creatinine | 7 | 2023 | 293 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1715 | 0.280 |
Why?
|
| Adolescent | 14 | 2022 | 9610 | 0.280 |
Why?
|
| Graft Survival | 4 | 2021 | 938 | 0.270 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.270 |
Why?
|
| Pathology, Surgical | 1 | 2007 | 13 | 0.270 |
Why?
|
| Child, Preschool | 10 | 2022 | 3832 | 0.270 |
Why?
|
| Complement System Proteins | 2 | 2024 | 86 | 0.260 |
Why?
|
| Polyomavirus Infections | 2 | 2017 | 28 | 0.260 |
Why?
|
| Nephrologists | 2 | 2025 | 13 | 0.260 |
Why?
|
| Tumor Virus Infections | 2 | 2017 | 83 | 0.260 |
Why?
|
| Antibodies, Antinuclear | 2 | 2006 | 94 | 0.250 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2006 | 12 | 0.250 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 20 | 0.250 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2006 | 14 | 0.250 |
Why?
|
| Fibrosis | 6 | 2022 | 230 | 0.250 |
Why?
|
| Cell Movement | 6 | 2024 | 804 | 0.250 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 157 | 0.250 |
Why?
|
| Giant Cells | 1 | 2006 | 18 | 0.250 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 39 | 0.240 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 701 | 0.240 |
Why?
|
| Albuminuria | 6 | 2013 | 51 | 0.230 |
Why?
|
| Microscopy, Electron | 5 | 2012 | 433 | 0.230 |
Why?
|
| Receptor, Anaphylatoxin C5a | 3 | 2015 | 21 | 0.230 |
Why?
|
| Mice, Knockout | 12 | 2024 | 2121 | 0.230 |
Why?
|
| Oxygen | 2 | 2013 | 769 | 0.230 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2013 | 60 | 0.230 |
Why?
|
| Nephritis, Hereditary | 1 | 2005 | 5 | 0.230 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2005 | 60 | 0.220 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2005 | 12 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 369 | 0.220 |
Why?
|
| Flow Cytometry | 2 | 2005 | 712 | 0.220 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2015 | 10 | 0.220 |
Why?
|
| Nephrology | 1 | 2025 | 46 | 0.220 |
Why?
|
| Oximetry | 1 | 2005 | 90 | 0.220 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2024 | 9 | 0.210 |
Why?
|
| CD11b Antigen | 2 | 2015 | 35 | 0.210 |
Why?
|
| Leiomyosarcoma | 1 | 2005 | 48 | 0.210 |
Why?
|
| Developing Countries | 1 | 2025 | 91 | 0.210 |
Why?
|
| Immunity, Humoral | 3 | 2020 | 74 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 187 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2020 | 1006 | 0.200 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 119 | 0.200 |
Why?
|
| Androgens | 1 | 2024 | 162 | 0.200 |
Why?
|
| Chicago | 4 | 2018 | 1464 | 0.200 |
Why?
|
| Immunoglobulin G | 6 | 2021 | 464 | 0.200 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2019 | 113 | 0.200 |
Why?
|
| Wireless Technology | 1 | 2023 | 21 | 0.200 |
Why?
|
| Education, Medical, Graduate | 1 | 2007 | 427 | 0.200 |
Why?
|
| Sickle Cell Trait | 2 | 2015 | 21 | 0.200 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2024 | 72 | 0.190 |
Why?
|
| Ureteral Obstruction | 3 | 2013 | 68 | 0.190 |
Why?
|
| Infant | 6 | 2020 | 3222 | 0.190 |
Why?
|
| Medicine | 1 | 2024 | 95 | 0.190 |
Why?
|
| Autoantigens | 3 | 2020 | 138 | 0.190 |
Why?
|
| Early Diagnosis | 1 | 2023 | 135 | 0.190 |
Why?
|
| Pathologists | 1 | 2023 | 40 | 0.190 |
Why?
|
| Receptors, Complement 3b | 4 | 2014 | 39 | 0.190 |
Why?
|
| Hepatitis | 1 | 2022 | 31 | 0.190 |
Why?
|
| HIV Infections | 1 | 2012 | 961 | 0.190 |
Why?
|
| Peptide Fragments | 3 | 2021 | 469 | 0.190 |
Why?
|
| Immunosuppressive Agents | 4 | 2015 | 990 | 0.190 |
Why?
|
| Nicotine | 1 | 2024 | 208 | 0.190 |
Why?
|
| Risk Factors | 6 | 2020 | 5912 | 0.180 |
Why?
|
| Nephrosis, Lipoid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Disease Management | 2 | 2025 | 359 | 0.180 |
Why?
|
| HLA-D Antigens | 1 | 2021 | 20 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 1546 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2023 | 2564 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 221 | 0.170 |
Why?
|
| Critical Care | 2 | 2015 | 444 | 0.170 |
Why?
|
| Serum Sickness | 4 | 2015 | 12 | 0.170 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2021 | 11 | 0.170 |
Why?
|
| Infant, Newborn | 4 | 2020 | 2482 | 0.170 |
Why?
|
| Kidney Function Tests | 4 | 2017 | 115 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 47 | 0.170 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2017 | 25 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 490 | 0.160 |
Why?
|
| Tunica Intima | 1 | 2021 | 61 | 0.160 |
Why?
|
| Apoptosis | 4 | 2016 | 1719 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 939 | 0.160 |
Why?
|
| Cyclohexanones | 1 | 2020 | 1 | 0.160 |
Why?
|
| Viologens | 1 | 2020 | 1 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2021 | 94 | 0.160 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 131 | 0.160 |
Why?
|
| Salts | 1 | 2020 | 18 | 0.160 |
Why?
|
| Liquid Crystals | 1 | 2020 | 13 | 0.160 |
Why?
|
| Cloud Computing | 1 | 2020 | 14 | 0.160 |
Why?
|
| Biomarkers | 6 | 2023 | 1912 | 0.160 |
Why?
|
| Paraproteinemias | 1 | 2020 | 19 | 0.160 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 1 | 2020 | 3 | 0.160 |
Why?
|
| Nephrons | 2 | 2010 | 16 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 306 | 0.160 |
Why?
|
| Neurofibroma | 1 | 2020 | 12 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2015 | 463 | 0.160 |
Why?
|
| Sarcoma, Synovial | 1 | 2020 | 20 | 0.160 |
Why?
|
| Glomus Tumor | 1 | 2020 | 10 | 0.160 |
Why?
|
| Arteries | 1 | 2021 | 171 | 0.150 |
Why?
|
| Lipoma | 1 | 2020 | 25 | 0.150 |
Why?
|
| Fibroma | 1 | 2020 | 30 | 0.150 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2010 | 46 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 2020 | 37 | 0.150 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 26 | 0.150 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 17 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2020 | 374 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 124 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 151 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 7073 | 0.140 |
Why?
|
| Terminology as Topic | 2 | 2017 | 219 | 0.140 |
Why?
|
| Blood Platelets | 3 | 2010 | 150 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2022 | 311 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2007 | 1092 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3835 | 0.140 |
Why?
|
| California | 2 | 2016 | 158 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 294 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 555 | 0.140 |
Why?
|
| Hospital Mortality | 2 | 2022 | 483 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2021 | 347 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2017 | 21 | 0.130 |
Why?
|
| Monocytes | 3 | 2014 | 215 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 45 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2018 | 9108 | 0.130 |
Why?
|
| Glomerular Mesangium | 4 | 2018 | 21 | 0.130 |
Why?
|
| Renin | 1 | 2017 | 67 | 0.130 |
Why?
|
| BK Virus | 1 | 2017 | 23 | 0.130 |
Why?
|
| Machine Learning | 1 | 2020 | 341 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2017 | 119 | 0.130 |
Why?
|
| Viremia | 1 | 2017 | 51 | 0.130 |
Why?
|
| Time Factors | 9 | 2018 | 5406 | 0.130 |
Why?
|
| Apoferritins | 4 | 2022 | 15 | 0.130 |
Why?
|
| Proteinuria | 3 | 2021 | 69 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 224 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2016 | 25 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2016 | 57 | 0.120 |
Why?
|
| Health Information Systems | 1 | 2016 | 7 | 0.120 |
Why?
|
| Parturition | 1 | 2016 | 21 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2017 | 234 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 2016 | 41 | 0.120 |
Why?
|
| Lymphocyte Depletion | 2 | 2013 | 102 | 0.120 |
Why?
|
| Coronary Care Units | 1 | 2015 | 5 | 0.120 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 159 | 0.120 |
Why?
|
| Data Mining | 1 | 2016 | 44 | 0.120 |
Why?
|
| Prognosis | 7 | 2021 | 3913 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2019 | 700 | 0.110 |
Why?
|
| Carboxypeptidases | 1 | 2015 | 34 | 0.110 |
Why?
|
| Cytogenetics | 2 | 2005 | 27 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 203 | 0.110 |
Why?
|
| Microvessels | 1 | 2015 | 68 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 49 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 21 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 226 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 131 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 875 | 0.110 |
Why?
|
| Germinal Center | 2 | 2016 | 62 | 0.110 |
Why?
|
| Vimentin | 1 | 2014 | 47 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2021 | 207 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2021 | 813 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2015 | 68 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2019 | 536 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2014 | 74 | 0.110 |
Why?
|
| Endothelial Cells | 3 | 2022 | 477 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2016 | 454 | 0.110 |
Why?
|
| Hemolysis | 1 | 2014 | 62 | 0.110 |
Why?
|
| Complement C3b | 1 | 2014 | 5 | 0.100 |
Why?
|
| Liver Failure | 1 | 2014 | 69 | 0.100 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2014 | 11 | 0.100 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 72 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2014 | 191 | 0.100 |
Why?
|
| Pulmonary Artery | 2 | 2006 | 333 | 0.100 |
Why?
|
| Critical Illness | 1 | 2016 | 343 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2015 | 170 | 0.100 |
Why?
|
| Leukocytes | 1 | 2015 | 210 | 0.100 |
Why?
|
| Curcumin | 1 | 2013 | 16 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 238 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 494 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 889 | 0.100 |
Why?
|
| Losartan | 2 | 2010 | 29 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 1002 | 0.100 |
Why?
|
| Jaundice | 1 | 2013 | 14 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 149 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 72 | 0.100 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 71 | 0.100 |
Why?
|
| Urothelium | 1 | 2013 | 67 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 192 | 0.100 |
Why?
|
| Renin-Angiotensin System | 2 | 2010 | 84 | 0.090 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 303 | 0.090 |
Why?
|
| Collagen Type IV | 2 | 2019 | 28 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 185 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 219 | 0.090 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 33 | 0.090 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2012 | 135 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2019 | 295 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2368 | 0.090 |
Why?
|
| Receptors, Complement | 2 | 2014 | 46 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 109 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 201 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 134 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 353 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2012 | 181 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2016 | 580 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 435 | 0.090 |
Why?
|
| Pregnancy | 2 | 2016 | 3148 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2013 | 224 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 249 | 0.080 |
Why?
|
| Aging | 3 | 2023 | 727 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 398 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 1584 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 140 | 0.080 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.080 |
Why?
|
| United States | 5 | 2022 | 7645 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2021 | 171 | 0.080 |
Why?
|
| Renal Artery | 1 | 2011 | 45 | 0.080 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2010 | 5 | 0.080 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 12 | 0.080 |
Why?
|
| Cicatrix | 1 | 2011 | 74 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 481 | 0.080 |
Why?
|
| Staining and Labeling | 2 | 2021 | 157 | 0.080 |
Why?
|
| Clone Cells | 1 | 2010 | 219 | 0.080 |
Why?
|
| Cardiac Output | 2 | 2010 | 141 | 0.080 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 50 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 22 | 0.080 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2010 | 13 | 0.080 |
Why?
|
| Tetralogy of Fallot | 1 | 2010 | 46 | 0.080 |
Why?
|
| Ice | 1 | 2010 | 11 | 0.080 |
Why?
|
| Antigens, CD | 3 | 2014 | 476 | 0.080 |
Why?
|
| Ventilator Weaning | 1 | 2010 | 40 | 0.080 |
Why?
|
| Complement C3 | 2 | 2007 | 58 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2010 | 89 | 0.080 |
Why?
|
| Angiomyolipoma | 1 | 2010 | 15 | 0.080 |
Why?
|
| Peer Review | 1 | 2010 | 21 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2011 | 118 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 688 | 0.080 |
Why?
|
| Ergocalciferols | 1 | 2010 | 38 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 608 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2010 | 122 | 0.080 |
Why?
|
| Canada | 1 | 2010 | 194 | 0.080 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2010 | 41 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2023 | 4565 | 0.080 |
Why?
|
| Vitamins | 1 | 2010 | 85 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 629 | 0.070 |
Why?
|
| Palatine Tonsil | 2 | 2021 | 32 | 0.070 |
Why?
|
| Receptors, Fc | 1 | 2009 | 38 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 90 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2015 | 409 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2010 | 623 | 0.070 |
Why?
|
| CD55 Antigens | 1 | 2009 | 21 | 0.070 |
Why?
|
| Prednisone | 2 | 2010 | 242 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 124 | 0.070 |
Why?
|
| Sepsis | 1 | 2013 | 388 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 288 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 148 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1723 | 0.070 |
Why?
|
| Ureter | 1 | 2009 | 92 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1980 | 0.070 |
Why?
|
| Integrin beta3 | 1 | 2008 | 31 | 0.070 |
Why?
|
| Hypertension | 1 | 2014 | 758 | 0.070 |
Why?
|
| Neoplasms | 1 | 2003 | 3171 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 408 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 53 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 759 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1993 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 2209 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 367 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 2023 | 262 | 0.060 |
Why?
|
| Pulse | 1 | 2006 | 14 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2019 | 2444 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2007 | 286 | 0.060 |
Why?
|
| Neprilysin | 1 | 2006 | 39 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2006 | 46 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 2889 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3479 | 0.060 |
Why?
|
| Rheumatic Heart Disease | 1 | 2006 | 28 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2017 | 351 | 0.060 |
Why?
|
| Brain | 2 | 2021 | 2375 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 2018 | 0.060 |
Why?
|
| Organelles | 1 | 2006 | 55 | 0.060 |
Why?
|
| Benzophenoneidum | 1 | 2005 | 1 | 0.060 |
Why?
|
| Mycobacterium avium Complex | 1 | 2005 | 6 | 0.060 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2024 | 797 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2005 | 65 | 0.060 |
Why?
|
| Lisinopril | 1 | 2005 | 6 | 0.060 |
Why?
|
| Chemokines | 2 | 2021 | 76 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2005 | 21 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2005 | 117 | 0.060 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2005 | 13 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2005 | 60 | 0.060 |
Why?
|
| Karyotyping | 1 | 2005 | 222 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 282 | 0.050 |
Why?
|
| Hematuria | 1 | 2005 | 49 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2005 | 57 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 264 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 639 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 292 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2005 | 49 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 2756 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 890 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 97 | 0.050 |
Why?
|
| Phenotype | 3 | 2017 | 2543 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 94 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 114 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2005 | 112 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2006 | 250 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2024 | 84 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 160 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 216 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 144 | 0.050 |
Why?
|
| Germ-Free Life | 1 | 2024 | 83 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2010 | 2828 | 0.050 |
Why?
|
| Catheterization | 1 | 2005 | 218 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1923 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2005 | 300 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2718 | 0.050 |
Why?
|
| Intelligence | 1 | 2024 | 67 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2023 | 10 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2019 | 962 | 0.050 |
Why?
|
| 12E7 Antigen | 1 | 2003 | 1 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2003 | 4 | 0.050 |
Why?
|
| Myogenin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Thy-1 Antigens | 1 | 2003 | 16 | 0.050 |
Why?
|
| Keratins | 1 | 2003 | 62 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 50 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2003 | 43 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2005 | 208 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 188 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 259 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2023 | 284 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 457 | 0.050 |
Why?
|
| Pediatricians | 1 | 2022 | 24 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 174 | 0.050 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
| Neoplastic Processes | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 333 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 379 | 0.040 |
Why?
|
| Osteopontin | 1 | 2021 | 48 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 83 | 0.040 |
Why?
|
| Peroxidase | 1 | 2021 | 54 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 1231 | 0.040 |
Why?
|
| Complement Pathway, Alternative | 1 | 2021 | 13 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2021 | 36 | 0.040 |
Why?
|
| Physical Conditioning, Animal | 1 | 2021 | 18 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 394 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 264 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 356 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2003 | 758 | 0.040 |
Why?
|
| Reperfusion | 1 | 2021 | 31 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1104 | 0.040 |
Why?
|
| Curriculum | 1 | 2025 | 594 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2465 | 0.040 |
Why?
|
| Antibodies | 2 | 2015 | 347 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 80 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1056 | 0.040 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2020 | 14 | 0.040 |
Why?
|
| Paraproteins | 1 | 2020 | 7 | 0.040 |
Why?
|
| Solutions | 1 | 2020 | 84 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2015 | 3061 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2021 | 229 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 1061 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2020 | 7 | 0.040 |
Why?
|
| Ganglion Cysts | 1 | 2020 | 5 | 0.040 |
Why?
|
| Synovial Cyst | 1 | 2020 | 17 | 0.040 |
Why?
|
| Fasciitis | 1 | 2020 | 13 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 537 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 2020 | 131 | 0.040 |
Why?
|
| Agrin | 1 | 2019 | 6 | 0.040 |
Why?
|
| Carcinoma | 1 | 2003 | 439 | 0.040 |
Why?
|
| Software | 1 | 2024 | 670 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 49 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 240 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2019 | 40 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2019 | 74 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 572 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 1950 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 86 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2806 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 75 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 49 | 0.040 |
Why?
|
| Laminin | 1 | 2019 | 89 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 198 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 424 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 293 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 143 | 0.040 |
Why?
|
| Light | 1 | 2020 | 287 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 2010 | 261 | 0.040 |
Why?
|
| Microbiota | 1 | 2024 | 425 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2018 | 25 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 193 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1933 | 0.030 |
Why?
|
| Peptides | 1 | 2021 | 654 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 132 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 790 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 52 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2017 | 58 | 0.030 |
Why?
|
| Hypoxia | 1 | 2022 | 675 | 0.030 |
Why?
|
| Plasma | 1 | 2017 | 50 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 729 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2017 | 48 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 173 | 0.030 |
Why?
|
| Rats | 1 | 2023 | 4042 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 702 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2010 | 408 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 154 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 1102 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 161 | 0.030 |
Why?
|
| Mice, Inbred NZB | 1 | 2016 | 13 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2016 | 20 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2017 | 43 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2016 | 41 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1866 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 374 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 70 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 602 | 0.030 |
Why?
|
| Virus Replication | 1 | 2017 | 284 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1661 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 16 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 26 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2010 | 896 | 0.030 |
Why?
|
| Biological Phenomena | 1 | 2016 | 5 | 0.030 |
Why?
|
| Data Curation | 1 | 2016 | 10 | 0.030 |
Why?
|
| Incidence | 2 | 2014 | 1702 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2016 | 41 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 412 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 98 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2011 | 407 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 760 | 0.030 |
Why?
|
| Heart Function Tests | 2 | 2006 | 28 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 178 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 117 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2016 | 49 | 0.030 |
Why?
|
| Complement C5a | 1 | 2015 | 24 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 580 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 1003 | 0.030 |
Why?
|
| CD18 Antigens | 1 | 2015 | 22 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 29 | 0.030 |
Why?
|
| Brachiocephalic Veins | 1 | 2015 | 31 | 0.030 |
Why?
|
| Melanoma | 1 | 2019 | 495 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 32 | 0.030 |
Why?
|
| Fistula | 1 | 2015 | 42 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Data Collection | 1 | 2016 | 370 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 137 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 136 | 0.030 |
Why?
|
| Heart Failure | 1 | 2005 | 1388 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1389 | 0.030 |
Why?
|
| Rituximab | 1 | 2015 | 128 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1365 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 204 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 331 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 278 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 42 | 0.030 |
Why?
|
| United Kingdom | 1 | 2014 | 190 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 198 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1528 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 313 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 40 | 0.020 |
Why?
|
| Interleukins | 1 | 2014 | 133 | 0.020 |
Why?
|
| Models, Biological | 2 | 2011 | 1768 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 292 | 0.020 |
Why?
|
| Atrophy | 1 | 2013 | 128 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 690 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 289 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 841 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 484 | 0.020 |
Why?
|
| Cell Communication | 1 | 2014 | 216 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2012 | 145 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 990 | 0.020 |
Why?
|
| Microscopy | 1 | 2012 | 89 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1173 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 300 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Palliative Care | 1 | 2014 | 269 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1735 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 571 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1525 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2014 | 541 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1103 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 917 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 996 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 505 | 0.020 |
Why?
|
| Oliguria | 1 | 2010 | 6 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 392 | 0.020 |
Why?
|
| Angiotensin I | 1 | 2010 | 7 | 0.020 |
Why?
|
| Suspensions | 1 | 2010 | 6 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 578 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1133 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 16 | 0.020 |
Why?
|
| Mesangial Cells | 1 | 2010 | 9 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1262 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2010 | 23 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 33 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2010 | 33 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2010 | 71 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 59 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 45 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2010 | 66 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2010 | 49 | 0.020 |
Why?
|
| Warm Ischemia | 1 | 2010 | 33 | 0.020 |
Why?
|
| Syndactyly | 1 | 2009 | 13 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 356 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 74 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1165 | 0.020 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 38 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 126 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 131 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 108 | 0.020 |
Why?
|
| Fibronectins | 1 | 2010 | 100 | 0.020 |
Why?
|
| World Health Organization | 1 | 2010 | 121 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 154 | 0.020 |
Why?
|
| Microvilli | 1 | 2009 | 44 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2009 | 37 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 190 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 959 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 315 | 0.020 |
Why?
|
| CD59 Antigens | 1 | 2009 | 17 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 203 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2302 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 456 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2009 | 271 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 239 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 248 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 713 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 271 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2009 | 169 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 587 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 572 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 505 | 0.020 |
Why?
|
| Arterioles | 1 | 2008 | 25 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2008 | 18 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2544 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 40 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 188 | 0.020 |
Why?
|
| Heart Rate | 1 | 2010 | 508 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 256 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 347 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 824 | 0.020 |
Why?
|
| Thermodilution | 1 | 2006 | 18 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1007 | 0.020 |
Why?
|
| Nuclear Pore | 1 | 2006 | 12 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 1139 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1260 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 868 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2592 | 0.010 |
Why?
|
| Epithelium | 1 | 2006 | 315 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 225 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 107 | 0.010 |
Why?
|
| Recurrence | 1 | 2008 | 1191 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 836 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2007 | 257 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 135 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 311 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2020 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 456 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 494 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1907 | 0.010 |
Why?
|